Influence of chronic cardiac failure severity on the course of comorbid type 2 diabetes mellitus
- Authors: Narusov O.Y.1, Lapina Y.V.1, Mareev V.Y.1, Bolotina M.G.1, Shestakova M.V.1, Masenko V.P.1, Baklanova N.A.1, Belenkov Y.N.1, Narusov OY.1, Lapina Y.V1, Mareev VY.1, Bolotina MG1, Shestakova MV1, Masenko VP1, Baklanova NA1, Belenkov Y.V1
-
Affiliations:
- Issue: Vol 81, No 9 (2009)
- Pages: 52-57
- Section: Editorial
- Submitted: 09.04.2020
- Published: 15.09.2009
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30507
- ID: 30507
Cite item
Full Text
Abstract
Material and methods. Time course changes of cerebral natriuretic peptide (CNUP) were used as a criterion of CCF severity in 81 patients with mild and moderate CCF (NYHA functional class II-III), left ventricular ejection fraction (LVEF) < 45% and type 2 DM. Of them, two groups of 19 patients each were compiled - with the highest and lowest CNUP levels. Also, patients with a rising CNUP level and CCF FC (n = 5) and those with decreasing CNUP and FC improvement (n = 33) were analysed. The following parameters were studied at baseline and 6 months later: clinicofunctional status, glomerular filtration rate (GFR), neurohormonal profile (CNUP), noradrenalin and angiotensin II, the level of HbA1c, baseline and postprandial plasma glucose, serum insulin and C-peptide.
Results. Insignificant changes in glycemia in low C-peptide were found in groups with mild CCF. In patients with high CNUP and CCF FC there was a positive correlation between high CNUP, noradrenalin and fasting glucose. With growing severity of CCF clinicofunctional status of the patients was deteriorating while levels of noradrenalin and angiotensin II tended to rise.
Conclusion. Moderate decompensation of CCF had no effect on the course of associated DM. More severe and long-term decompensation may be accompanied with noticeable changes in glycemia.
About the authors
Oleg Yur'evich Narusov
Email: narusov@rambler.ru
Yuliya Valer'evna Lapina
Vyacheslav Yur'evich Mareev
Email: prov_mareev@ossn.ru
Marina Grigor'evna Bolotina
Email: bolot999@mail.ru
Marina Vladimirovna Shestakova
Email: nephro@endocrincentr.ru
Valeriy Pavlovich Masenko
Email: massenko@mail.ru
Natal'ya Aleksandrovna Baklanova
Email: valbakl@gmail.com
Yuriy Nikitich Belenkov
O Yu Narusov
Yu V Lapina
V Yu Mareev
M G Bolotina
M V Shestakova
V P Masenko
N A Baklanova
Yu V Belenkov
References
- Amato L., Paolisso G., Cacciatore F. et al. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. Diabet. Metab. 1997; 23 (3): 213- 218.
- Paolisso G., Riu S. D., Marrazo G. et al. Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. Metabolism 1991; 40 (9): 972-977.
- Witteles R. M., Wilson Tang W. H., Jamali A. H. et al. Insulin resistance in idiopathic dilated cardiomyopathy. A possible etiologic link. J. Am. Coll. Cardiol. 2004; 44 (1): 78-81.
- Swan J. W., Anker S. D., Walton C. et al. Insulin resistance in chronic heart failure relation to severity and etiology of heart failure. J. Am. Coll. Cardiol. 1997; 30 (2): 527-532.
- Suskin N., McKelvie R. S., Burns R. J. et al. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur. Heart J. 2000; 21 (16): 1368- 1375.
- Swan J. W., Walton C., Godsland I. F. et al. Insulin resistance in chronic heart failure. Eur. Heart J. 1994; 15 (11): 1528- 1532.
- Диденко В. А., Симонов Д. В. Связь концентрации инсулина в крови с состоянием ренин-ангиотензин-альдостероновой системы и клинической картины гипертонической болезни. Тер. арх. 1999; 71 (1): 26-31.
- Lind L., Lithell H. Decreased peripheral blood flow in the pathogenesis of the metabolic syndrome comprising hypertension, hyperlipidemia, and hyperinsulinemia. Am. Heart J. 1993; 125 (5pt 2): 1494-1497.
- Ольбинская Л. И. Метаболический синдром у больных с ХСН: подходы к лечению. Сердеч. недостат. 2003; 4 (1): 12-14.
- Гиляревский С. Р. Эффективность применения блокаторов рецепторов АII при метаболическом синдроме. Сердце 2005; 4 (6): 340-343.
- Шестакова М. В., Чугунова Л. А., Шамхалова М. Ш. Телмисартан - новый нефропротектор при сахарном диабете: результаты международных и российского исследований. Consilium Medicum 2006; 8 (9): 35-38.
- Paolisso G., Tagliamonte M. R., Rizzo M. R. et al. Prognostic importance of insulin-mediated glucose uptake in aged patients with congestive heart failure secondary to mitral and/or aortic valve disease. Am. J. Cardiol. 1999; 83 (9): 1338-1344.
- Suskin N., McKelvie R. S., Rouleau J. et al. Increased insulin and glucose levels in heart failure. J. Am. Coll. Cardiol. 1998; 31 (suppl. A): 249A.